Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: HutchMed Announces $1.1 Billion Deal with Takeda for Colorectal Cancer Drug

Week in Review: Mabwell Out-Licenses Rare Disease Drug for $412.5 Million

Week in Review: Qitan Raises $101 Million for Nanopore Sequencing Devices

Week in Review: WuXi Biologics Out-Licenses Four TCE Antibodies to GSK in $1.5 Billion Pact

Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China